With big pharma circling psychedelics, the next breakthrough may not come from tripping at all

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been viewed as a fringe pursuit, scientifically intriguing, but clinically and commercially fraught. AbbVie’s decision to pay up for access to Gilgamesh’s pipeline marked a clear shift: big pharma is officially buying into the promise of neuroplastogens, molecules that repair and rewire brain circuits disrupted in psychiatric disease. But as much as the AbbVie and Gilgamesh deal validated the field, it also raised a deeper question: which companies are building drugs that can realistically scale into everyday psychiatric practice? The post With big pharma circling psychedelics, the next breakthrough may not come from tripping at all appeared first on Microdose.